Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vincristine liposomal - Acrotech Biopharma

Drug Profile

Vincristine liposomal - Acrotech Biopharma

Alternative Names: Marqibo; Sphingosomal vincristine; Vincacine; Vincristine sulfate injection; Vincristine sulfate liposomes injection; VSLI

Latest Information Update: 28 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Acrotech Biopharma; CASI Pharmaceuticals; Hana Biosciences; Inex Pharmaceuticals Corporation; Talon Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Vinca alkaloids
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase I/II Cancer
  • No development reported Multiple myeloma
  • Discontinued Colorectal cancer; Malignant melanoma; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 28 May 2019 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (IV, Injection)
  • 07 Mar 2019 National Medical Products Administration, China approves Clinical Trial Application for a registrational trial in Precursor cell lymphoblastic leukaemia lymphoma
  • 06 Mar 2019 Spectrum Pharmaceuticals completes sale of vincristine liposomal to Acrotech Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top